Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612 | 1.00 | CNR2 (0.41) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL978536 | 1.00 | CNR2 (0.41) | CNR2FKBP1ACA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL186334 | 0.98 | CNR2 (0.40) | CNR2FKBP1ACA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL23211020 | 0.98 | CNR2 (0.40) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL27797009 | 0.85 | CA12 (0.40) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL14569608 | 0.83 | SMN1; SMN2 (0.39) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL4471485 | 0.83 | SMN1; SMN2 (0.39) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL4471494 | 0.83 | SMN1; SMN2 (0.39) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL16160604 | 0.82 | CNR2 (0.38) | CNR2FKBP1ACA12CA1CA9 | |
| SCHEMBL3939459 | 0.82 | CNR2 (0.38) | CNR2FKBP1ACA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4289842-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2023-12-13 | — | — | EP | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11661431-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220389034-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022166923-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | 和博医药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1735311-B1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1735311-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005111037-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | CNR2 4399/4885FKBP1A 498/4885CA12 1905/4885 |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CNR2 422/4885FKBP1A 983/4885CA12 4338/4885 |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885 |
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | IL1B, IL1A, ADRA2B | CNR2 84/4885FKBP1A 4364/4885CA12 1610/4885 |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | NFKBIA, IRAK2, IRAK1 | CNR2 95/4885FKBP1A 649/4885CA12 4690/4885 |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | NFKBIA, NFKB2, IKBKG | CNR2 94/4885FKBP1A 682/4885CA12 4624/4885 |
| US-11661431-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | CNR2 422/4885FKBP1A 983/4885CA12 4338/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885 |
| US-20220389034-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CNR2 422/4885FKBP1A 983/4885CA12 4338/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | CNR2 1555/4885FKBP1A 382/4885CA12 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.